{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:29:17Z","timestamp":1792290557343,"version":"4.4.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,16]],"date-time":"2018-01-16T00:00:00Z","timestamp":1516060800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","atherosclerosis-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.atherosclerosis.2017.11.027","type":"journal-article","created":{"date-parts":[[2017,12,2]],"date-time":"2017-12-02T01:01:40Z","timestamp":1512176500000},"page":"205-210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"special_numbering":"C","title":["PCSK9 inhibitors in clinical practice: Delivering on the promise?"],"prefix":"10.1016","volume":"270","author":[{"given":"Robert M.","family":"Stoekenbroek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merel L.","family":"Hartgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4499-5092","authenticated-orcid":false,"given":"Roger","family":"Rutte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1893-4250","authenticated-orcid":false,"given":"Douwe D.","family":"de Wijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik S.G.","family":"Stroes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Kees","family":"Hovingh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2017.11.027_bib1","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","author":"Ference","year":"2017","journal-title":"Eur. Heart J."},{"issue":"17","key":"10.1016\/j.atherosclerosis.2017.11.027_bib2","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy\u2014European Atherosclerosis society consensus Panel statement on assessment, aetiology and management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur. Heart J."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2017.11.027_bib3","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","article-title":"Very low levels of atherogenic lipoproteins and the risk for cardiovascular events","volume":"64","author":"Boekholdt","year":"2014","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"issue":"13","key":"10.1016\/j.atherosclerosis.2017.11.027_bib4","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1177\/2047487317717346","article-title":"Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: the role of PCSK9 inhibitors","volume":"24","author":"Pe\u0107in","year":"2017","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"25","key":"10.1016\/j.atherosclerosis.2017.11.027_bib5","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2017.11.027_bib6","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12916-015-0358-8","article-title":"Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials","volume":"13","author":"Zhang","year":"2015","journal-title":"BMC Med."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2017.11.027_bib7","doi-asserted-by":"crossref","first-page":"40","DOI":"10.7326\/M14-2957","article-title":"Effects of proprotein convertase subtilisin\/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis","volume":"163","author":"Navarese","year":"2015","journal-title":"Ann. Intern Med."},{"key":"10.1016\/j.atherosclerosis.2017.11.027_bib8","first-page":"1","article-title":"Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration","volume":"0","author":"Ference","year":"2017","journal-title":"Eur. Heart J."},{"issue":"18","key":"10.1016\/j.atherosclerosis.2017.11.027_bib9","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2017.11.027_bib10","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.jacl.2017.05.001","article-title":"Update on the use of PCSK9 inhibitors in adults: recommendations from an Expert Panel of the national lipid association","volume":"11","author":"Orringer","year":"2017","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2017.11.027_bib11","author":"National Institute for Health and Care Excellence (NICE)"},{"key":"10.1016\/j.atherosclerosis.2017.11.027_bib12","author":"National Institute for Health and Care Excellence (NICE)"},{"issue":"29","key":"10.1016\/j.atherosclerosis.2017.11.027_bib13","first-page":"2245","article-title":"European Society of Cardiology\/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin\/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk","volume":"38","author":"Landmesser","year":"2017","journal-title":"Eur. Heart J."},{"issue":"10","key":"10.1016\/j.atherosclerosis.2017.11.027_bib14","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.numecd.2014.05.009","article-title":"Resistance and intolerance to statins","volume":"24","author":"Reiner","year":"2014","journal-title":"Nutr. Metab. Cardiovasc Dis."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2017.11.027_bib15","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1358\/dot.2015.51.12.2435830","article-title":"Alirocumab: targeting PCSK9 to treat hypercholesterolemia","volume":"51","author":"Pecin","year":"2015","journal-title":"Drugs Today (Barc)"},{"issue":"suppl_J","key":"10.1016\/j.atherosclerosis.2017.11.027_bib16","doi-asserted-by":"crossref","first-page":"J9","DOI":"10.1016\/S1520-765X(02)90077-5","article-title":"Ezetimibe: efficacy and safety in clinical trials","volume":"4","author":"Ballantyne","year":"2002","journal-title":"Eur. Hear J. Suppl."},{"key":"10.1016\/j.atherosclerosis.2017.11.027_bib17","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.atherosclerosis.2017.08.013","article-title":"Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: results from the Dyslipidemia International Study II","volume":"266","author":"Gitt","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2017.11.027_bib18","unstructured":"Steen DL, Khan I, Ansell D, Sanchez RJ, Ray KK. Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines."},{"issue":"39","key":"10.1016\/j.atherosclerosis.2017.11.027_bib19","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2017.11.027_bib20","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.atherosclerosis.2013.09.020","article-title":"Treatment potential for dyslipidaemia management in patients with coronary heart disease across Europe: findings from the EUROASPIRE III survey","volume":"231","author":"Reiner","year":"2017","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2017.11.027_bib21","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.cjca.2012.05.007","article-title":"Proportion and risk indicators of nonadherence to statin therapy: a meta-analysis","volume":"28","author":"Lemstra","year":"2017","journal-title":"Can. J. Cardiol."},{"issue":"10","key":"10.1016\/j.atherosclerosis.2017.11.027_bib22","article-title":"Systematic review and network meta-analysis on the efficacy of evolocumab and other therapies for the management of lipid levels in hyperlipidemia","volume":"6","author":"Toth","year":"2017","journal-title":"J.\u00a0Am. Heart Assoc."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2017.11.027_bib23","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jacl.2012.03.003","article-title":"Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users","volume":"6","author":"Cohen","year":"2012","journal-title":"J.\u00a0Clin. Lipidol."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2017.11.027_bib24","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.2174\/1381612820666141013134447","article-title":"Adverse effects of statins - myths and reality","volume":"21","author":"Simic","year":"2015","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.atherosclerosis.2017.11.027_bib25","author":"Gupta","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2017.11.027_bib26","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1001\/jama.288.4.462","article-title":"Adherence with statin therapy in elderly patients with and without acute coronary syndromes","volume":"288","author":"Jackevicius","year":"2002","journal-title":"JAMA"},{"issue":"38","key":"10.1016\/j.atherosclerosis.2017.11.027_bib27","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1093\/eurheartj\/eht295","article-title":"Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences","volume":"34","author":"Chowdhury","year":"2013","journal-title":"Eur. Heart J."},{"issue":"15","key":"10.1016\/j.atherosclerosis.2017.11.027_bib28","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2016.3608","article-title":"Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance","volume":"315","author":"Nissen","year":"2016","journal-title":"Jama"},{"issue":"23","key":"10.1016\/j.atherosclerosis.2017.11.027_bib29","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","article-title":"Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab","volume":"63","author":"Stroes","year":"2014","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2017.11.027_bib30","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","article-title":"Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial","volume":"9","author":"Moriarty","year":"2015","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2017.11.027_bib31","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.13032","article-title":"Pro-protein subtilisin kexin-9 (PCSK9) inhibition in practice: lipid clinic experience in 2 contrasting UK centres","author":"Kohli","year":"2017","journal-title":"Int. J. Clin. Pract."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2017.11.027_bib32","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jacl.2017.02.014","article-title":"Proprotein convertase subtilisin\/kexin 9 inhibition in patients with familial hypercholesterolemia: initial clinical experience","volume":"11","author":"Galema-Boers","year":"2017","journal-title":"J.\u00a0Clin. Lipidol."},{"issue":"16","key":"10.1016\/j.atherosclerosis.2017.11.027_bib33","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2017.11.027_bib34","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.jacl.2017.05.016","article-title":"Long-term treatment adherence to the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2 years","volume":"11","author":"Farnier","year":"2017","journal-title":"J.\u00a0Clin. Lipidol."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915017314120?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915017314120?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T16:08:24Z","timestamp":1693325304000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915017314120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":34,"alternative-id":["S0021915017314120"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.11.027","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PCSK9 inhibitors in clinical practice: Delivering on the promise?","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.11.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}